Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Practicality of Prophylactic Aflibercept to Reduce Diabetic Retinopathy Progression

Practicality of Prophylactic Aflibercept to Reduce Diabetic Retinopathy Progression Randomized Clinical Trial of Anti-VEGF to Prevent PDR and CI-DME Original Investigation Research Invited Commentary Practicality of Prophylactic Aflibercept to Reduce Diabetic Retinopathy Progression Rajendra S. Apte, MD, PhD; Christopher K. Hwang, MD, PhD Anti–vascular endothelial growth factor (VEGF) therapy has In Protocol S, patients with PDR at baseline were randomly as- revolutionized the treatment of diabetic retinopathy, includ- signed to receive PRP or ranibizumab. Participants who re- ing diabetic macular edema and proliferative diabetic reti- ceived ranibizumab initially received injections every 4 weeks nopathy (PDR). Diabetic Retinopathy Clinical Research (DRCR) for the first 4 to 6 injections, and subsequent injections could Retina Network Protocol S be deferred based on investigator discretion if neovascular- and the Clinical Efficacy of ization had stabilized or resolved. During the second year, the Related article page 701 Intravitreal Aflibercept Ver- follow-up visit interval could gradually be extended from ev- sus Panretinal Photocoagulation for Best Corrected Visual Acu- ery 4 weeks to every 16 weeks. For eyes with PDR without vi- ity in Patients With Proliferative Diabetic Retinopathy at 52 sion-impairing CI-DME at baseline in the ranibizumab group, Weeks (CLARITY) trials demonstrated superior visual acuity the median number of injections was 10 (interquartile range, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

Practicality of Prophylactic Aflibercept to Reduce Diabetic Retinopathy Progression

JAMA Ophthalmology , Volume 139 (7) – Jul 30, 2021

Loading next page...
 
/lp/american-medical-association/practicality-of-prophylactic-aflibercept-to-reduce-diabetic-Yj1RRU0hQi
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
2168-6165
eISSN
2168-6173
DOI
10.1001/jamaophthalmol.2021.0624
Publisher site
See Article on Publisher Site

Abstract

Randomized Clinical Trial of Anti-VEGF to Prevent PDR and CI-DME Original Investigation Research Invited Commentary Practicality of Prophylactic Aflibercept to Reduce Diabetic Retinopathy Progression Rajendra S. Apte, MD, PhD; Christopher K. Hwang, MD, PhD Anti–vascular endothelial growth factor (VEGF) therapy has In Protocol S, patients with PDR at baseline were randomly as- revolutionized the treatment of diabetic retinopathy, includ- signed to receive PRP or ranibizumab. Participants who re- ing diabetic macular edema and proliferative diabetic reti- ceived ranibizumab initially received injections every 4 weeks nopathy (PDR). Diabetic Retinopathy Clinical Research (DRCR) for the first 4 to 6 injections, and subsequent injections could Retina Network Protocol S be deferred based on investigator discretion if neovascular- and the Clinical Efficacy of ization had stabilized or resolved. During the second year, the Related article page 701 Intravitreal Aflibercept Ver- follow-up visit interval could gradually be extended from ev- sus Panretinal Photocoagulation for Best Corrected Visual Acu- ery 4 weeks to every 16 weeks. For eyes with PDR without vi- ity in Patients With Proliferative Diabetic Retinopathy at 52 sion-impairing CI-DME at baseline in the ranibizumab group, Weeks (CLARITY) trials demonstrated superior visual acuity the median number of injections was 10 (interquartile range,

Journal

JAMA OphthalmologyAmerican Medical Association

Published: Jul 30, 2021

References